Beijing Scitech-MQ Pharmaceuticals Ltd. described receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of cancer.
China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have patented benzimidazole compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disease and inflammatory disorders.
Research at Genfleet Therapeutics Inc. has led to the development of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors have been reported in an Immuneering Corp. patent as potentially useful for the treatment of cancer.
Guangzhou Kaishi Pharmaceutical Co. Ltd. has patented treprostinil derivatives acting as nitric oxide (NO) donors reported to be useful for the treatment of acute respiratory distress syndrome, pulmonary arterial hypertension and arterial occlusion.
Recludix Pharma Inc. has disclosed signal transducer and activator of transcription 3 (STAT3) and/or STAT6 inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Bright Minds Biosciences Inc. has created phenethlyamines acting as 5-HT2A receptor agonists and reported to be useful for the treatment of depression and anxiety disorders.
Research at Beigene Co. Ltd. has led to the identification of new proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moiety covalently linked to a Bruton tyrosine kinase (BTK) targeting moiety via linker. They are reported to be useful for the treatment of cancer.
Heteroaryl compounds acting as interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors are described in a recent Accro Bioscience (HK) Ltd. patent. They are reported to be useful for the treatment of endometriosis, systemic lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis, primary central nervous system and diffuse large B-cell lymphoma.
RSS
